The Pitt-Ohio State Clinical Trials Unit (Pitt-OSU CTU), and its two Clinical Research Sites (CRSs) at the University of Pittsburgh (Pitt CRS) in Pittsburgh, PA, and The Ohio State University (OSU CRS) in Columbus, Ohio, is a high performing CTU that is vital for both scientific and administrative leadership in the DAIDS networks for HIV Therapeutics and HIV Prevention. The Pitt-OSU CTU proposes to continue its productive affiliations with the AIDS Clinical Trials Group (ACTG) and the HIV Prevention Trials Network (HPTN). Additionally, the Pitt-OSU CTU is poised to expand further in terms of scientific capabilities and access to both affected and at risk populations to participate in the HIV Vaccine Trials Network (HVTN). As such, the Pitt-OSU CTU will contribute to the research agendas of several DAIDS HIV/AIDS Clinical Trials Networks and thereby achieve the desired efficiency for a CTU.
The Aims of this application are: 1) to continue to advance the scientific agenda of the DAIDS HIV/AIDS Therapeutic and Prevention networks by developing and implementing high-priority research studies as key protocol team members, by serving on major network leadership and scientific committees, and by directing the ACTG Laboratory Center (LC) Virology and Immunology Specialty Laboratories; 2) to recruit, enroll, retain and monitor study participants in high-priority protocols of the DAIDS networks, and to meet and exceed performance standards established by these networks; 3) to engage with partners in our communities, including Columbus, Ohio, located in Franklin County (one of the 48 counties in the US with the highest HIV burden) to support implementation science initiatives consistent with the national ?Ending the HIV Epidemic Plan?; 4) to partner with affected communities and community advisory boards at each CRS throughout these endeavors; and 5) to mentor young investigators identified at each CRS to become skilled, independent researchers. The key scientific areas of focus in HIV therapeutics will include HIV reservoirs and control of HIV replication in the absence of ART (?ART-free remission?); novel and long-acting interventions for the treatment of HIV; and prevention and treatment of HIV-related non-infectious co-morbidities and Hepatitis B. In HIV Prevention, the Pitt-OSU CTU will utilize skills and expertise developed over the past decade to focus on long- acting antiretroviral agents and delivery systems for Pre-exposure Prophylaxis (PrEP); evaluation of multipurpose prevention technologies (MPTs) and broadly neutralizing antibodies for HIV prevention; and integrated strategies for HIV prevention. The collective expertise, administrative efficiency, and performance record of the Pitt-OSU CTU and its CRSs over the last grant cycle ensure that these Specific Aims are achievable and that the Pitt-OSU CTU will make important contributions to the research agendas of DAIDS-sponsored networks, with the ultimate goal of ending the AIDS epidemic.

Public Health Relevance

The Pitt-Ohio State Clinical Trials Unit is a collaborative effort that will support the DAIDS HIV/AIDS research networks with a particular focus on critical areas of research in HIV therapy and prevention including: control of HIV replication in the absence of ART (?ART-free remission?), long-acting treatment for HIV; prevention and treatment of non-infectious comorbidities and hepatitis B; and HIV prevention strategies including pre-exposure prophylaxis, multipurpose technologies, broadly neutralizing antibodies and vaccines.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Coates, Cindy Karen
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pittsburgh
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187
Kearney, Mary F; Spindler, Jonathan; Wiegand, Ann et al. (2018) Lower pre-ART intra-participant HIV-1 pol diversity may not be associated with virologic failure in adults. PLoS One 13:e0190438
Montgomery, Elizabeth T; Noguchi, Lisa M; Dai, James Y et al. (2018) Acceptability of and Adherence to an Antiretroviral-Based Vaginal Microbicide among Pregnant Women in the United States. AIDS Behav 22:402-411
Benson, Constance A; Andersen, Janet W; Macatangay, Bernard J C et al. (2018) Safety and Immunogenicity of Zoster Vaccine Live in Human Immunodeficiency Virus-Infected Adults With CD4+ Cell Counts >200 Cells/mL Virologically Suppressed on Antiretroviral Therapy. Clin Infect Dis 67:1712-1719
Mhlanga, Felix G; Noguchi, Lisa; Balkus, Jennifer E et al. (2018) Implementation of a prospective pregnancy registry for antiretroviral based HIV prevention trials. HIV Clin Trials 19:8-14
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459
Riddler, Sharon A; Zheng, Lu; Durand, Christine M et al. (2018) Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART. Open Forum Infect Dis 5:ofy242
Gandhi, Monica; Gandhi, Rajesh T; Stefanescu, Andrei et al. (2018) Cumulative Antiretroviral Exposure Measured in Hair Is Not Associated With Measures of HIV Persistence or Inflammation Among Individuals on Suppressive ART. J Infect Dis 218:234-238
Park, You Jeong; Etemad, Behzad; Ahmed, Hayat et al. (2017) Impact of HLA Class I Alleles on Timing of HIV Rebound After Antiretroviral Treatment Interruption. Pathog Immun 2:431-445

Showing the most recent 10 out of 114 publications